Shopping Cart 0
Cart Subtotal
USD 0

Karolinska Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Karolinska Institutet (KI) is a medical university that offers education services. The university provides education and research in the fields of medicine and health sciences. Its education courses include audiology, biomedicine, biomedical lab science, dental hygiene, medicine, nursing, occupational therapy and others. KI offers optometry, physiotherapy, psychology, public health science, speech and language pathology, and radiography. KI provides supplementary training on midwifery, and psychotherapy. It offers healthcare, education, research and development. The university's research areas include cancer and hematology, cell, molecular and structural biology, endocrinology and metabolism, epidemiology and public health sciences, and health care sciences. KI is headquartered in Stockholm, Sweden.

Karolinska Institute-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karolinska Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Karolinska Institute, Medical Devices Deals, 2012 to YTD 2018 11

Karolinska Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Karolinska Institute, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

RXi Pharma and Karolinska Institutet Enter into Research Partnership 14

LIDDS Enters into Research Agreement with Karolinska Institute 15

Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 16

NeuroVive Pharma Enters into Agreement with Karolinska Institutet 17

Karolinska Institutet Partners with Johnson & Johnson Companies 18

Canqura Oncology Enters into Agreement with Karolinska Institutet 19

Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 20

Sprint Bioscience Enters into Research Agreement with Karolinska Institutet 21

Scancell Extends Research Agreement with Karolinska Institutet 22

Biovica Enters into Research Agreement with Karolinska Institutet 23

Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 24

Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 25

Thermo Fisher Scientific Enters into Agreement with Karolinska Institute 26

Idogen Partners with Karolinska Institutet 27

Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 28

Karolinska University Hospital Enters Into Research Agreement With GE Healthcare For Cell Therapy 29

Licensing Agreements 30

Oblique Therapeutics Enters Licensing Agreement with National Institutes of Health and Karolinska Institutet 30

Karolinska Institute-Key Competitors 31

Karolinska Institute-Key Employees 32

Karolinska Institute-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Corporate Communications 34

Apr 07, 2017: Government re-appoints four members of the KI board 34

Government and Public Interest 35

Sep 14, 2018: NIH grant of 526,000 USD to Craig Wheelock 35

Aug 31, 2018: Similar changes in the brains of patients with ADHD and emotional instability 36

Aug 26, 2018: Oxygen therapy for patients suffering from a heart attack does not prevent heart failure 37

Aug 23, 2018: Treatment for severe heartburn prevents cancer 38

Aug 23, 2018: Dramatic development of immune system after birth 39

Aug 15, 2018: Prestigious grant for research on ALS 41

Aug 08, 2018: New method reveals cell development 42

Aug 06, 2018: Red blood cells cause cardiovascular injury in type 2 diabetes 43

Jul 25, 2018: New potential target for treatment of diabetes 44

Jul 24, 2018: Karolinska Institute: New potential target for treatment of diabetes 45

Jul 17, 2018: Sleep disorders can be associated with increased risk of dementia 46

Jul 04, 2018: Solvents and smoking are associated with increased risk of MS 47

Jun 28, 2018: Newly detected stop signal in cell division prevents cancer 48

Jun 25, 2018: LIDDS' NanoZolid technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technology 49

Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 50

May 31, 2018: Inefficient fat degradation can be behind obesity 51

May 31, 2018: Fat degradation helps the tumor grow in case of acid deficiency 52

May 28, 2018: Anti-inflammatory treatment stops aggressive childhood cancer 53

May 25, 2018: Karolinska Institutet: Aggression neurons identified 54

May 21, 2018: Cell types underlying schizophrenia identified 55

May 18, 2018: New strategy for curing chronic hepatitis B infection 56

May 17, 2018: New strategy to cure chronic hepatitis B infection 57

Apr 24, 2018: Imagined and real movements are controlled by the brain in the same way 58

Apr 19, 2018: KI researchers awarded grants from the Swedish Childhood Cancer Foundation 59

Apr 17, 2018: New disease model to facilitate development of ALS and MS drugs 60

Apr 05, 2018: PCSK9 inhibitors have unexpected anti-inflammatory effects 61

Mar 13, 2018: New biomarkers for childhood cancer neuroblastoma 62

Mar 08, 2018: Fluoroquinolones linked to increased risk of acute aortic disease 63

Mar 06, 2018: Karolinska Institute: The body's glucostat identified 64

Mar 01, 2018: Promising therapeutic approach for spinal cord injuries 65

Mar 01, 2018: New promising approach to healing spinal cord injuries 66

Feb 28, 2018: Lithium treatment for bipolar disorder linked to lowest risk of rehospitalisation 67

Feb 23, 2018: Stem cell study may result in stronger muscles in old age 68

Feb 14, 2018: Karolinska Institutet: Atlas of brain blood vessels provides fresh clues to brain diseases 69

Feb 13, 2018: New method maps the dopamine system in parkinson patients 70

Feb 06, 2018: Asthma medicine possible treatment for pulmonary edema 71

Jan 23, 2018: Reduced dental anxiety among children with internet-based CBT 72

Jan 19, 2018: Factor that doubles the risk of death from breast cancer identified 73

Jan 18, 2018: New method to stop cells dividing could help fight cancer 74

Jan 17, 2018: New way to stop the growth of breast cancer cells 75

Jan 16, 2018: Oxysterols guide gut immune cells and are involved in inflammatory bowel disease 76

Jan 12, 2018: Karolinska Institutet: Genetic analysis can improve depression therapy 77

Jan 12, 2018: Gene analysis can provide better treatment for depression 78

Jan 09, 2018: Large-scale protein analysis can provide new possibilities for diagnosis and treatment in dementia 79

Dec 22, 2017: Salamander genome gives clues about unique regenerative ability 80

Dec 05, 2017: Karolinska Institute: Polyunsaturated fatty acids linked to reduced allergy risk 81

Dec 04, 2017: Karolinska Institute: New approach to predict respiratory allergy in early childhood 82

Nov 20, 2017: Enterovirus vaccine prevents virus-induced diabetes in a Type 1 diabetes experimental model 83

Oct 25, 2017: Thrombotic drugs are associated with decreased dementia risk in atrial fibrillation 84

Oct 24, 2017: Blood-thinning drugs appear to protect against dementia as well as stroke in AF patients 85

Oct 09, 2017: Karolinska Institutet: Safe to treat dementia patients with clot-busting drugs 87

Oct 04, 2017: Asthma increases the risk of complications during pregnancy and childbirth 88

Sep 21, 2017: Inflammatory bowel disease in childhood associated with increased risk of cancer 89

Sep 12, 2017: Relapse rare in young men after antireflux surgery 90

Aug 30, 2017: Thorough analysis reveals immune system dynamics after immunotherapy 91

Aug 28, 2017: Anti-inflammatory drugs can inhibit muscle growth 92

Aug 18, 2017: Oral contraceptives linked to reduced risk of rheumatoid arthritis 93

Aug 09, 2017: Method developed that gives researchers better conditions for studying insulin-producing cells 94

Jul 18, 2017: Fewer infections in mechanical heart valves 95

Jul 11, 2017: New tool demonstrates differences in human immune systems 96

Jun 22, 2017: Presence of protein important clue to tumour regression in neuroblastoma 97

Jun 22, 2017: The presence of the protein KIF1B? can play a central role for the outcome of a neuroblastoma diagnosis 98

Jun 09, 2017: Lithium medication protects against suicide 99

Jun 07, 2017: Fewer relapses in schizophrenia with long-acting injections 100

Jun 06, 2017: New possible target for cancer treatment 101

May 24, 2017: Making biological drugs with spider silk protein 102

May 22, 2017: New findings on formation and malformation of blood vessels 103

May 17, 2017: New way of preventing pneumococcal brain invasion 104

May 16, 2017: Spread of tau protein measured in the brains of Alzheimer's patients 105

May 15, 2017: Corticosteroid treatment increases survival of preterm infants within hours 106

May 08, 2017: Newly discovered malaria mechanism gives hope to pregnant women 107

Mar 14, 2017: Major research project provides new clues to schizophrenia 108

Feb 20, 2017: Hope for new treatment for Huntington's disease 109

Feb 07, 2017: NattoPharma Named Partner For Horizon 2020 EU Research Grant 110

Product News 111

Jul 11, 2017: New potential treatment for aggressive types of childhood cancer 111

Mar 12, 2018: Aggressive breast cancer can be transformed into a treatable form 112

Feb 15, 2018: Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment of advanced cancer 113

Feb 02, 2018: Successful NK cell-based immunotherapy for leukaemia 114

Jan 12, 2017: Inhibition of EZH2 might be new therapy of multiple myeloma 115

Other Significant Developments 116

Sep 04, 2018: New project to improve drugs safety in East Africa 116

Aug 27, 2018: Microvascular dysfunction: a common cause of heart failure with preserved pumping capacity 117

Aug 09, 2018: Karolinska Institute: Detailed atlas of the nervous system 118

Jul 30, 2018: LCSB researchers predict cell conversion factors 119

Jul 06, 2018: Re search ers de ve lop a new method for turn ing skin cells into pluri po tent stem cells 120

Jun 26, 2018: AI could improve prostate cancer diagnosis and treatment 121

Jun 11, 2018: Immune system does not recover despite cured hepatitis C infection 123

Jun 11, 2018: Genome-editing tool could increase cancer risk 124

Jun 26, 2017: KCC improves patient safety of advanced therapy drugs 125

Appendix 126

Methodology 126

About GlobalData 126

Contact Us 126

Disclaimer 126


List Of Figure

List of Figures

Karolinska Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karolinska Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Karolinska Institute, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Karolinska Institute, Pharmaceuticals & Healthcare, Key Facts 2

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Karolinska Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Karolinska Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Karolinska Institute, Deals By Therapy Area, 2012 to YTD 2018 10

Karolinska Institute, Medical Devices Deals, 2012 to YTD 2018 11

Karolinska Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

RXi Pharma and Karolinska Institutet Enter into Research Partnership 14

LIDDS Enters into Research Agreement with Karolinska Institute 15

Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 16

NeuroVive Pharma Enters into Agreement with Karolinska Institutet 17

Karolinska Institutet Partners with Johnson & Johnson Companies 18

Canqura Oncology Enters into Agreement with Karolinska Institutet 19

Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 20

Sprint Bioscience Enters into Research Agreement with Karolinska Institutet 21

Scancell Extends Research Agreement with Karolinska Institutet 22

Biovica Enters into Research Agreement with Karolinska Institutet 23

Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 24

Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 25

Thermo Fisher Scientific Enters into Agreement with Karolinska Institute 26

Idogen Partners with Karolinska Institutet 27

Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 28

Karolinska University Hospital Enters Into Research Agreement With GE Healthcare For Cell Therapy 29

Oblique Therapeutics Enters Licensing Agreement with National Institutes of Health and Karolinska Institutet 30

Karolinska Institute, Key Competitors 31

Karolinska Institute, Key Employees 32

Karolinska Institute, Other Locations 33

Karolinska Institute, Subsidiaries 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Karolinska Institute, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.